Differences

This shows you the differences between two versions of the page.

--- jessica_hopkins [2022/01/06 11:04]
liam
+++ jessica_hopkins [2022/01/30 01:08] (current)
liam [Ontario COVID-19 Science Advisory Table]
@@ Line 4: / Line 4: @@
 Dr. **Jessica Hopkins** is employed at the [[Dalla Lana School of Public Health]] at the [[University of Toronto]], [[McMaster University]], and [[Public Health Ontario]]. She is also Co-Chair of the [[Ontario Immunization Advisory Committee]] (OIAC), and formerly held lead Officer positions for Hamilton and Niagara, and Peel Health Region. She is registered to practice medicine at [[Limeridge Medical Centre]].
+===== Affiliations =====
+==== Limeridge Medical Centre ====
+Hopkins is registered with the [[College of Physicians and Physicians]] (CPSO) to practice medicine at [[Limeridge Medical Centre]] in Hamilton, Ontario.((//Hopkins, Jessica Patricia - Doctor Details.// College of Physicians and Surgeons of Ontario. Retrieved December 12, 2021, from https://doctors.cpso.on.ca/DoctorDetails/Hopkins-Jessica---Patricia/0210039-80671))
+==== McMaster University ====
+Hopkins is an Assistant Professor in Health Research Methods, Evidence and Impact in the Faculty of Health Sciences at [[McMaster University]].((//Jessica Hopkins.// McMaster University. Retrieved December 12, 2021, from https://experts.mcmaster.ca/display/hopkij1))
+==== Ontario COVID-19 Science Advisory Table ====
+Hopkins is a member of the [[Ontario COVID-19 Science Advisory Table]].((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved January 29, 2022, from https://covid19-sciencetable.ca/about/#hopkins-jessica)) In this capacity, Hopkins urged parents to inject their children with a [[COVID-19]] product as soon as they were approved by the [[National Advisory Committee on Immunization]] (NACI), as well as all of their caregivers.((Cross, J. S. (2021, August 26). //Public Health Ontario urging parents to immunize young children against COVID-19 as soon as vaccines are approved.// QP Briefing. https://www.qpbriefing.com/2021/08/26/public-health-ontario-urging-parents-to-immunize-young-children-against-covid-19-as-soon-as-vaccines-are-approved/))
+==== Ontario Medical Association ====
+Hopkins has served as a member on the Physician Services Committee of the [[Ontario Medical Association]], for which she received “remuneration for travel and accommodation”.((Hopkins, J. (2021, August 23). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/11/Declaration-of-Interest_Science-Table_Jessica-Hopkins_20210823.pdf))
+==== Public Health Agency of Canada ====
+Hopkins is a member of the Technical Advisory Committee for COVID-19 under the [[Public Health Agency of Canada]] (PHAC).((Hopkins, J. (2021, May 25). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/11/Declaration-of-Interest_Science-Table_Hopkins_20210525.pdf))
+==== Public Health Ontario ====
+Hopkins is the Chief Health Protection and Emergency Preparedness Officer at [[Public Health Ontario]]. Her listed areas of expertise are public health, communicable diseases, surveillance and epidemiology, and public health policy. Her COVID-19 research activities under PHO are “examining child and family policies”, “collaborating on understanding mask use in schools through simulation”, and “collaboration on public health syndromic surveillance using people-driven data”.((//Dr. Jessica Hopkins.// (2021, January 6). Public Health Ontario. https://www.publichealthontario.ca/en/about/research/our-researchers/jessica-hopkins))
+==== University of Toronto ====
+Hopkins is an Adjunct Lecturer with the [[Dalla Lana School of Public Health]] at the [[University of Toronto]], in the Clinical Public Health Division. Her research interests are “applied public health practice and communicable disease control”.((Dalla Lana School of Public Health. (2018, June 14). //Hopkins, Jessica.// University of Toronto. https://www.dlsph.utoronto.ca/faculty-profile/hopkins-jessica/))
+===== Publications =====
+Hopkins' relevant studies featured by her profiles on U of T and McMaster’s websites include:
+  * //Impact of COVID-19 pre-test probability on positive predictive value of high cycle threshold SARS-CoV-2 real-time reverse transcription PCR test results.//((Gubbay, J. B., Rilkoff, H., Kristjanson, H. L., Forbes, J. D., Murti, M., Eshaghi, A., Broukhanski, G., Corbeil, A., Fittipaldi, N., Hopkins, J. P., Kristjanson, E., Kus, J. V., Macdonald, L., Majury, A., Mallo, G. V., Mazzulli, T., Melano, R. G., Olsha, R., Perusini, S. J., & Tran, V. (2021). //Impact of COVID-19 pre-test probability on positive predictive value of high cycle threshold SARS-CoV-2 real-time reverse transcription PCR test results.// Infection Control & Hospital Epidemiology, 1–18. https://doi.org/10.1017/ice.2021.369))
+    * Conclusion: “Large-scale SARS-CoV-2 screening testing initiatives among low pre-test probability populations [patients who are not symptomatic and/or don’t have a confirmed contact with a person sick with COVID-19] should be evaluated thoroughly prior to implementation given the risk of false positives and consequent potential for harm at the individual and population level.”
+  * //S-Gene Target Failure as a Marker of Variant B.1.1.7 Among SARS-CoV-2 Isolates in the Greater Toronto Area, December 2020 to March 2021//((Brown, K. A., Gubbay, J., Hopkins, J., Patel, S., Buchan, S. A., Daneman, N., & Goneau, L. W. (2021). //S-Gene Target Failure as a Marker of Variant B.1.1.7 Among SARS-CoV-2 Isolates in the Greater Toronto Area, December 2020 to March 2021.// JAMA, 325(20), 2115. https://doi.org/10.1001/jama.2021.5607))
+  * //The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada//((Maharaj, A. S., Parker, J., Hopkins, J. P., Gournis, E., Bogoch, I. I., Rader, B., Astley, C. M., Ivers, N., Hawkins, J. B., VanStone, N., Tuite, A. R., Fisman, D. N., Brownstein, J. S., & Lapointe-Shaw, L. (2021). //The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada.// The Lancet Infectious Diseases, 21(5), 593–594. https://doi.org/10.1016/s1473-3099(21)00151-1))
+    * Funded by the Department of Medicine COVID-19 Funding Opportunity from the [[University of Toronto]]
+  * //Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy//((Mustafa, R. A., Santesso, N., Khatib, R., Mustafa, A. A., Wiercioch, W., Kehar, R., Gandhi, S., Chen, Y., Cheung, A., Hopkins, J., Ma, B., Lloyd, N., Wu, D., Broutet, N., & Schünemann, H. J. (2016). //Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy.// International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics, 132(3), 259–265. https://doi.org/10.1016/j.ijgo.2015.07.024))
+    * Commissioned and funded by the [[World Health Organization]] (WHO)
+  * //Antivirals for Treatment of Influenza: A Systematic Review and Meta-analysis of Observational Studies//((Hsu, J., Santesso, N., Mustafa, R., Brozek, J., Chen, Y. L., Hopkins, J. P., Cheung, A., Hovhannisyan, G., Ivanova, L., Flottorp, S. A., Sæterdal, I., Wong, A. D., Tian, J., Uyeki, T. M., Akl, E. A., Alonso-Coello, P., Smaill, F., & Schünemann, H. J. (2012). //Antivirals for Treatment of Influenza.// Annals of Internal Medicine, 156(7), 512. https://doi.org/10.7326/0003-4819-156-7-201204030-00411))
+    * Funded by the [[World Health Organization]] (WHO) and [[McMaster University]]
+  * //Evaluation of the ability of standardized supports to improve public health response to syndromic surveillance for respiratory diseases in Canada//((Rivera, L. A., Li, Y., Savage, R. D., Crowcroft, N. S., Bolotin, S., Rosella, L. C., Lou, W., Hopkins, J., Gemmill, I., & Johnson, I. (2017). //Evaluation of the ability of standardized supports to improve public health response to syndromic surveillance for respiratory diseases in Canada.// BMC Public Health, 17(1). https://doi.org/10.1186/s12889-017-4073-6))
+    * Funded by the [[Canadian Institutes of Health Research]] (CIHR)
+  * //World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2–3 and screen-and-treat strategies to prevent cervical cancer//((Santesso, N., Mustafa, R. A., Schünemann, H. J., Arbyn, M., Blumenthal, P. D., Cain, J., Chirenje, M., Denny, L., De Vuyst, H., Eckert, L. O., Forhan, S. E., Franco, E. L., Gage, J. C., Garcia, F., Herrero, R., Jeronimo, J., Lu, E. R., Luciani, S., Quek, S. C., & Sankaranarayanan, R. (2016). //World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer.// International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics, 132(3), 252–258. https://doi.org/10.1016/j.ijgo.2015.07.038))
+    * Funded by the [[World Health Organization]] (WHO), [[Flanders International Cooperation Agency]], [[Institut National du Cancer]] (National Cancer Institute in France), and [[gavi|Gavi, the Vaccine Alliance]]